Avoro Ventures — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)Bryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)David Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Board seatBehzad Aghazadeh· per SEC Form D · $100M raise · filed Mar 2025
Co-investors3B Future Health FundAlly Bridge GroupDecheng CapitalVivo CapitalOrbiMed
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.